Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 154664
Gene Symbol: ABCA13
ABCA13 		0.010 Biomarker disease BEFREE CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. 25889687 2015
Entrez Id: 55289
Gene Symbol: ACOXL
ACOXL 		0.100 GeneticVariation disease GWASCAT Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 28346442 2017
Entrez Id: 207
Gene Symbol: AKT1
AKT1 		0.010 Biomarker disease BEFREE Our data suggest that AKT and pAKT are unfavorable prognostic factors for ovarian serous adenocarcinoma and clear cell carcinomas whereas nm23-H1 expression predicates favorable patient prognosis. 18949358 2008
Entrez Id: 216
Gene Symbol: ALDH1A1
ALDH1A1 		0.010 AlteredExpression disease BEFREE Our study supports that ALDH1A1 expression is associated with poor response to platinum-based therapy in patients with high-grade ovarian serous carcinoma. 28851663 2018
Entrez Id: 238
Gene Symbol: ALK
ALK 		0.310 GeneticVariation disease UNIPROT
Entrez Id: 238
Gene Symbol: ALK
ALK 		0.310 AlteredExpression disease BEFREE ALK expression was detected in 23/85 (27.1%) ovarian serous carcinoma and 0/25 (0%) in ovarian mucinous carcinoma. 27271776 2016
Entrez Id: 154796
Gene Symbol: AMOT
AMOT 		0.010 Biomarker disease BEFREE Our results uncover a novel PKCι-AMOT-YAP1 signaling axis that promotes OSC tumor growth, and provide a rationale for therapeutic targeting of this pathway for treatment of OSC. 27321186 2017
Entrez Id: 307
Gene Symbol: ANXA4
ANXA4 		0.010 Biomarker disease BEFREE In addition, upregulation and nuclear translocation of ANXA4 have been observed in the progression of colorectal cancer and ovarian serous carcinoma. 27100483 2016
Entrez Id: 324
Gene Symbol: APC
APC 		0.010 Biomarker disease BEFREE Our data provide evidence of heterogeneity in ovarian serous carcinoma and identify APC, MAPK3, BAG3 and S100A10 as potential biomarkers of poor chemotherapy response and/or poor outcome in this cancer. 26232338 2015
Entrez Id: 335
Gene Symbol: APOA1
APOA1 		0.010 AlteredExpression disease BEFREE APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. 24926085 2014
Entrez Id: 6311
Gene Symbol: ATXN2
ATXN2 		0.100 GeneticVariation disease GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191 2016
Entrez Id: 6790
Gene Symbol: AURKA
AURKA 		0.010 AlteredExpression disease BEFREE BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. 24756216 2014
Entrez Id: 9212
Gene Symbol: AURKB
AURKB 		0.020 AlteredExpression disease BEFREE BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. 24756216 2014
Entrez Id: 9212
Gene Symbol: AURKB
AURKB 		0.020 AlteredExpression disease BEFREE Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. 23114921 2013
Entrez Id: 29086
Gene Symbol: BABAM1
BABAM1 		0.100 GeneticVariation disease GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191 2016
Entrez Id: 29086
Gene Symbol: BABAM1
BABAM1 		0.100 GeneticVariation disease GWASCAT Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 28346442 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.020 GeneticVariation disease BEFREE Activation of MAPK is regulated by upstream kinases including KRAS and BRAF, which are frequently mutated in low-grade ovarian serous carcinoma. 15475429 2004
Entrez Id: 673
Gene Symbol: BRAF
BRAF 		0.020 GeneticVariation disease BEFREE Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 12644542 2003
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1 		0.030 GeneticVariation disease BEFREE Mutations of TP53 and dysfunction of the Brca1 and/or Brca2 tumor-suppressor proteins have been implicated in the molecular pathogenesis of a large fraction of OSCs, but frequent somatic mutations in other well-established tumor-suppressor genes have not been identified. 19048115 2008
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1 		0.030 GeneticVariation disease BEFREE The aim of this study was to identify the frequency and spectrum of germline and somatic BRCA1/2 alterations in a group of Polish patients with ovarian serous carcinoma. 27167707 2016
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1 		0.030 Biomarker disease BEFREE Our goal was to assess whether immunohistochemical analysis (IHC) for BRCA1 is an effective method for the detection of BRCA1 dysfunction in molecularly characterized high-grade ovarian serous carcinoma. 23232854 2013
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2 		0.110 GeneticVariation disease GWASCAT Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 27197191 2016
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2 		0.110 GeneticVariation disease BEFREE We show that olaparib alone and in combination with carboplatin greatly inhibit growth in BRCA2-mutated ovarian serous carcinoma. 21097693 2011
Entrez Id: 699
Gene Symbol: BUB1
BUB1 		0.010 AlteredExpression disease BEFREE BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. 24756216 2014
Entrez Id: 811
Gene Symbol: CALR
CALR 		0.010 AlteredExpression disease BEFREE Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. 24060004 2013